NCT06606314
Specified Drug-use Surveillance of Fabhalta Capsules
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 14 with changes below, 1 re-verified with no change.
- Minor Trial completed
- Primary completion date changed from estimate of Sep 30, 2028 to Oct 15, 2026
- Study sites: 91 to 90
- Minor Site details revised at 66 of 91 sitesv14
- Minor Site details revised at 4 of 91 sitesv13
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Enrollment increased: 100 → 132 participants
- Study sites: 92 to 91
- Minor Study sites: 91 to 92v10
Show 8 earlier versionsHide 8 earlier versions
- Minor Study sites: 81 to 91v9
- Minor Study sites: 74 to 81v8
- Minor Study sites: 65 to 74v7
- Minor Study sites: 48 to 65v6
- Minor Study sites: 42 to 48v5
- Minor Study sites: 8 to 42
- Start date: Sep 19, 2024 to Sep 18, 2024
- Minor Study sites: 1 to 8v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Dec 1, 2024 to Sep 19, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Occurrence status of infections.
Timeframe: 48weeks
Secondary (3)
Occurrence status of serious hemolysis after discontinuation of Fabhalta.
Occurrence status of adverse events and adverse drug reactions.
Incidence of breakthrough hemolysis and change of hemolysis-related markers and status of red blood cell transfusion-free.
Sites
90 sites in 1 country